ArticleiScience2026

Quantitative systems pharmacology modeling of class I-III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design.

Jingjing Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.